Last reviewed · How we verify
Debio 0123 and Sacituzumab govitecan
Debio 0123 and Sacituzumab govitecan is a Small molecule drug developed by MedSIR. It is currently in Phase 1 development. Also known as: Trodelvy.
At a glance
| Generic name | Debio 0123 and Sacituzumab govitecan |
|---|---|
| Also known as | Trodelvy |
| Sponsor | MedSIR |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Debio 0123 and Sacituzumab govitecan CI brief — competitive landscape report
- Debio 0123 and Sacituzumab govitecan updates RSS · CI watch RSS
- MedSIR portfolio CI
Frequently asked questions about Debio 0123 and Sacituzumab govitecan
What is Debio 0123 and Sacituzumab govitecan?
Debio 0123 and Sacituzumab govitecan is a Small molecule drug developed by MedSIR.
Who makes Debio 0123 and Sacituzumab govitecan?
Debio 0123 and Sacituzumab govitecan is developed by MedSIR (see full MedSIR pipeline at /company/medsir).
Is Debio 0123 and Sacituzumab govitecan also known as anything else?
Debio 0123 and Sacituzumab govitecan is also known as Trodelvy.
What development phase is Debio 0123 and Sacituzumab govitecan in?
Debio 0123 and Sacituzumab govitecan is in Phase 1.
Related
- Manufacturer: MedSIR — full pipeline
- Also known as: Trodelvy
- Compare: Debio 0123 and Sacituzumab govitecan vs similar drugs
- Pricing: Debio 0123 and Sacituzumab govitecan cost, discount & access